In addition, a broad predictive analysis allows identification of genomic aberrations that are rarely considered by clinicians, e.g. MSI in a non-MSI-prone tumor or a KIT mutation in melanoma, which might be beneficial for treatment options [5, 51, 52]. The gene discussed is KIT; the disease is melanoma.